Day: September 22, 2025

REYKJAVIK, ICELAND (September 22, 2024) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) has adopted a positive opinion recommending approval for AVT03, Alvotech’s proposed biosimilar to Prolia® (denosumab 60 mg/mL single use pre-filed syringe) and Xgeva® (denosumab 70 mg/mL single use vial). Pending approval, the biosimilar will be marketed by Alvotech’s commercial partners, STADA Arzneimittel AG (“STADA”) and Dr. Reddy’s Laboratories SA (“Dr. Reddy’s”), each partner with semi-exclusive commercial rights in Europe, including Switzerland and the UK. “We look forward to working with our partners in making denosumab available more...

HONG KONG, Sept. 22, 2025 (GLOBE NEWSWIRE) — GPTBots.ai, the enterprise AI platform of Aurora Mobile (NASDAQ: JG), co-hosted the highly anticipated thematic course “AI Agents Drive Intelligent Transformation” with the Hong Kong Productivity Council (HKPC). The course successfully concluded at the HKPC Building.The event brought together enterprise leaders and AI innovators to delve into digital and intelligent upgrades, systematically analyzing the practical applications of AI Agents across end-to-end business scenarios. It provided Hong Kong enterprises with fresh perspectives and actionable strategies to overcome transformation bottlenecks and embrace cutting-edge AI innovation.(Photo by GPTBots) This training session not only delivered cutting-edge AI technologies and invaluable practical experience to local businesses...

LTA appoints Grab to operate WeRide autonomous vehicles on two designated routes in Punggol, Singapore Ai.R features two WeRide vehicle models: a five-seater GXR and an eight-seater Robobus WeRide marks its first deployment of GXRs in Singapore and Southeast Asia Ai.R vehicles have passed Singapore’s stringent Milestone 1 (M1) assessment, proving they can safely navigate on public roads GrabAcademy and WeRide have started training private-hire and taxi drivers as autonomous vehicle Safety OperatorsSINGAPORE, Sept. 22, 2025 (GLOBE NEWSWIRE) — WeRide (Nasdaq: WRD), a global leader in autonomous driving technology, announced that it will be deploying its GXRs and Robobus vehicles in Singapore as part of Ai.R, Grab’s first autonomous vehicle (AV) service for Singapore consumers. Ai.R, short for Autonomously Intelligent Ride,...

New smartphone license agreement drives projected ARR1 to all-time high of $579 million WILMINGTON, Del., Sept. 22, 2025 (GLOBE NEWSWIRE) — InterDigital, Inc. (Nasdaq: IDCC), a mobile, video and AI technology research and development company, today announced that it has signed a new license agreement with a major Chinese smartphone vendor and has raised its outlook for third quarter 2025. “This new license agreement, which was concluded through amicable negotiation, adds another major smartphone player to our customer base and increases our projected annualized recurring revenue (ARR) by approximately $26 million to a record $579 million,” commented Liren Chen, CEO and President, InterDigital. “Following our $1 billion deal with Samsung, we continue our track record of strong execution across the business and...

REYKJAVIK, ICELAND and LONDON, Sept. 22, 2025 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) has adopted a positive opinion recommending approval for Gobivaz®, Alvotech’s proposed biosimilar to Simponi® (golimumab), a biologic used to treat several chronic inflammatory diseases. “We look forward to working with Advanz Pharma to increase access for patients and healthcare professionals to golimumab, as the reference...

REYKJAVIK, ICELAND and LONDON, UK (September 22, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) has adopted a positive opinion recommending approval for Gobivaz®, Alvotech’s proposed biosimilar to Simponi® (golimumab), a biologic used to treat several chronic inflammatory diseases. “We look forward to working with Advanz Pharma to increase access for patients and healthcare professionals to golimumab, as the reference biologic Simponi®...

C4X Discovery Holdings Ltd C4X Discovery announces selection of a once-daily development candidate from its α4β7 inhibitor programme A potent and selective α4β7 inhibitor with oral bioavailability to support once-daily dosing 22 September 2025 – C4X Discovery Holdings Ltd (“C4XD”), a pioneering Drug Discovery company, today announces the selection of a potential best-in-class pre-clinical candidate from its oral α4β7 integrin inhibitor programme for the treatment of inflammatory bowel disease (IBD). The selected candidate supports once-daily dosing and presents a potentially transformative oral therapy for IBD patients. IBD, which affects more than five million people worldwide1, represents a rapidly growing market projected to reach USD 47.7 billion by 20342. With many patients still underserved by current therapies, C4X...

The share repurchase programme runs as from 26 February 2025 and up to and including 30 January 2026 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 2.25 billion, cf. Corporate Announcement No. 3/2025 of 26 February 2025. The share repurchase programme is initiated and structured in compliance with the EU Commission Regulation No. 596/2014 of 16 April 2014, the so-called “Market Abuse Regulation”, and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”). The following transactions have been made under the program:  Number of shares Average purchase price (DKK) Transaction value (DKK)Accumulated, previous announcement 1,959,088 600.65 1,176,730,31515 September 2025 8,816 701.69 6,186,11916 September...

Enlight Research updated its valuation of INVL Technology, a company that invests in IT businesses which is seeking to divest its portfolio of investments, following the publication of operating results for the first half of 2025.   Analyst Mattias Wallander, who performed the valuation for Enlight Research, increased the target price for INVL Technology’s shares to EUR 4.25 per share, which he said implies a price-to-sales multiple of 0.9x. Enlight’s previous sum-of-the-parts base case fair value target price was EUR 4.12 per share. Before publication of the update report, INVL Technology’s share price on the Nasdaq Vilnius stock exchange was EUR 3.56. “The current net asset value (NAV) discount of 19% is slightly below the long-term average of 22%. In our view, an exit at attractive levels could trigger a decline of the NAV discount...